Sprint Bioscience AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was SEK 34.35 million compared to SEK 5.19 million a year ago. Revenue was SEK 33.9 million compared to SEK 6.79 million a year ago. Net income was SEK 17.57 million compared to net loss of SEK 5.99 million a year ago. Basic earnings per share from continuing operations was SEK 0.54 compared to basic loss per share from continuing operations of SEK 0.36 a year ago. For the nine months, sales was SEK 34.38 million compared to SEK 15.43 million a year ago. Revenue was SEK 34.32 million compared to SEK 18.12 million a year ago. Net loss was SEK 10.04 million compared to SEK 28.27 million a year ago. Basic loss per share from continuing operations was SEK 0.33 compared to SEK 1.68 a year ago.